ARTICLE | Clinical News

Stelara ustekinumab regulatory update

January 19, 2015 8:00 AM UTC

The U.K.’s NICE issued draft guidance recommending Stelara ustekinumab from Johnson & Johnson alone or in combination with methotrexate to treat active psoriatic arthritis only when tumor necrosis factor (TNF) alpha inhibitors are contraindicated but would otherwise be considered or the patient has had treatment with ³1 TNF alpha inhibitors. The recommendation is contingent on a patient access scheme in which the company provides the 90 mg dose of Stelara for patients who weigh >100 kg at the cost of the 45 mg dose. ...